Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
David Einhorn's Trump-Proof Investment Plan
18 Stocks Moving In Friday's Pre-Market Session
DSW: Why Morgan Stanley And The Rest Of The Bears Are Wrong (Seeking Alpha)
Related PFE
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Boeing, Pfizer And Others Band Together To Ask Congress For More Taxes
Why 'D Printing and Biotech Will Be Good Bets in —…–7 (GuruFocus)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Jan 2017JefferiesDowngradesBuyHold
Jan 2017Standpoint ResearchUpgradesHoldBuy
Dec 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

View Comments and Join the Discussion!